S. Ou

发表

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2012, Molecular Cancer Therapeutics.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014, The New England journal of medicine.

ROS1 rearrangements define a unique molecular class of lung cancers.

Jeffrey W. Clark, Julie M. Batten, A. Iafrate, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2012 .

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

J. Szustakowski, P. Stephens, C. Rudin, 2018, Cancer discovery.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2011, The Lancet. Oncology.

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.

S. Ou, T. Reungwetwattana, Ying-ying Liang, 2017, Lung cancer.

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2015 .

Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.

A. Shaw, S. Ou, Gregory Riely, 2012 .

SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)

S. Ou, D. Gandara, J. Testa, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

P. Stephens, J. Ross, M. Rosenzweig, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Jeffrey W. Clark, A. Drilon, M. Socinski, 2017 .

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

S. Ou, V. Miller, Siraj M. Ali, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.

A. Shaw, S. Ou, T. Mok, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States

S. Ou, H. Lin, Yu Yin, 2022, JTO clinical and research reports.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

S. Ou, Shannon S Zhang, 2022, Lung Cancer.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

P. Stephens, S. Ou, Siraj M. Ali, 2016, JAMA oncology.

Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature.

S. Ou, M. Ando, A. Kubo, 2014, Lung cancer.

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.

S. Ou, Siraj M. Ali, A. Schrock, 2017, Lung cancer.

Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke.

S. Ou, M. Kitaichi, M. Takada, 2012, Clinical lung cancer.

Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.

S. Ou, A. Dash, S. Klempner, 2014, The oncologist.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

P. Stephens, S. Ou, B. Halmos, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neuregulin 1 Fusion-Positive NSCLC.

S. Ou, M. Nagasaka, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

A. Iafrate, M. Socinski, S. Ou, 2014 .

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

S. Ou, V. Miller, Siraj M. Ali, 2015, Lung cancer.

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.

S. Ou, V. Miller, Siraj M. Ali, 2016, Lung cancer.

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

H. Wakelee, L. Sequist, S. Ou, 2015 .

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

S. Ou, V. Miller, Siraj M. Ali, 2016, Lung cancer.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Manish B. Patel, A. Iafrate, A. Drilon, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments

S. Ou, P. Bycott, E. Cohen, 2014, Cancer.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

P. Stephens, D. Lipson, S. Ou, 2018, The oncologist.

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Gettinger, S. Ou, 2012 .

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.

M. Kris, P. Jänne, S. Ou, 2012 .

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing

S. Ou, J. Swensen, W. Korn, 2020, JTO clinical and research reports.

ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer.

S. Ou, V. Zhu, 2016, Translational lung cancer research.

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

S. Ou, S. Klempner, A. Raufi, 2015, Translational lung cancer research.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

J. Shih, S. Ou, V. Miller, 2010 .

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

M. Ladanyi, A. Iafrate, M. Mino‐Kenudson, 2013, Clinical Cancer Research.

Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2013 .

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

S. Ou, Siraj M. Ali, A. Schrock, 2017, Lung Cancer.

Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations.

S. Ou, T. Reungwetwattana, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

M. Maitland, A. Tolcher, S. Ou, 2016, Journal of Hematology & Oncology.

Liquid Biopsy to Identify Actionable Genomic Alterations.

S. Ou, M. Nagasaka, V. Zhu, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

S. Ou, J. Abbruzzese, V. Subbiah, 2021 .

Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.

J. Neal, S. Ou, Jianchang Lin, 2021 .

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

A. Shaw, S. Ou, T. Mok, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

A. Shaw, S. Ou, Gregory Riely, 2018 .

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

M. Socinski, A. Shaw, S. Ou, 2016, The Lancet. Oncology.

Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature.

S. Ou, M. Ando, A. Kubo, 2012 .

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2021, Annals of Oncology.

Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.

A. Shaw, S. Ou, B. Solomon, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

S. Ou, R. Madison, A. Schrock, 2020, JTO clinical and research reports.

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases

S. Ou, N. Robinette, Kunil K. Raval, 2020, Lung Cancer.

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

S. Ou, Siraj M. Ali, J. Milliken, 2017, Lung cancer.

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

S. Ou, M. Ahn, N. Segal, 2016 .

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)

A. Drilon, A. Shaw, S. Ou, 2019, Annals of Oncology.

Pacific Rim redux: lorlatinib, the ultimate Jaeger?

S. Ou, V. Zhu, 2018, Annals of translational medicine.

Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

S. Ou, S. Klempner, 2015, Chinese clinical oncology.

Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases

S. Ou, Siraj M. Ali, A. Borghei, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

A. Shaw, S. Ou, F. de Marinis, 2019, Lung Cancer.

Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al.

S. Ou, J. Pasi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).

M. Socinski, A. Shaw, S. Ou, 2015 .

Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

R. Govindan, J. Ahn, S. Ou, 2015 .

STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

A. Drilon, A. Shaw, S. Ou, 2015 .

Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.

M. Maitland, A. Tolcher, S. Ou, 2014 .

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

P. Stephens, S. Ou, V. Miller, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

M. Ladanyi, M. Berger, A. Drilon, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

L. Sequist, S. Ou, T. Mok, 2015, The Lancet. Oncology.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2013 .

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

P. Hegde, E. Sokol, S. Ou, 2022, NPJ precision oncology.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

C. Paweletz, J. Christensen, S. Ou, 2022, The New England journal of medicine.

Impact of environmental tobacco smoke (ETS) on ALK rearrangements in never smokers (NS) with non-small cell lung cancer (NSCLC): Analyses on a prospective multinational ETS registry.

S. Ou, M. Ahn, M. Ando, 2013 .

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Drilon, M. Socinski, 2016 .

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

S. Ou, 2011, Drug design, development and therapy.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017, The New England journal of medicine.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Ruey-min Lee, S. Ou, Gregory Riely, 2014, The Lancet. Oncology.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

S. C. Wang, A. Iafrate, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled Analysis of the Literature

S. Ou, M. Ando, A. Kubo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

A. Iafrate, A. Drilon, M. Mino‐Kenudson, 2017, JCO precision oncology.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

A. Drilon, A. Shaw, S. Ou, 2018, Cancer discovery.

First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.

P. Jänne, A. Shaw, S. Ou, 2018 .

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.

A. Drilon, S. Ou, J. Tabernero, 2020 .

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.

S. Ou, J. Ying, Yan Wang, 2020, Lung cancer.

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

P. Jänne, Qinying Zhao, H. Wakelee, 2020, Clinical Cancer Research.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

A. Drilon, F. Cappuzzo, S. Ou, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

A. Drilon, A. Shaw, S. Ou, 2016 .

Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

J. McPherson, P. Stephens, J. Riess, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first‐line treatment of advanced non‐small cell lung cancer: a generic protocol

A. Drilon, S. Ou, N. Syn, 2018 .

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.

N. Girard, S. Ou, L. Bazhenova, 2022, Lung cancer.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

S. Ou, V. Miller, Siraj M. Ali, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

A. Shaw, S. Ou, Gregory Riely, 2018, The Lancet. Oncology.

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

P. Jänne, D. Root, R. Heist, 2021, Experimental and Molecular Therapeutics.

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

S. Ou, M. Nagasaka, V. Zhu, 2020, JTO clinical and research reports.

CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.

S. Ou, V. Zhu, 2019, Lung cancer.

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer

P. Stephens, A. Shaw, S. Ou, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

S. Ou, T. Reungwetwattana, 2015, Translational lung cancer research.

Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.

P. Stephens, S. Ou, V. Miller, 2015, Lung cancer.

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

S. Ou, R. Soong, R. Soo, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

E. Sokol, K. Abhishek, S. Ganesan, 2019, The oncologist.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Lucio Crinò, Benjamin Solomon, Patrick Schnell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Advanced Lung Cancer

S. Ou, Coty Ho, 2009 .

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

Joon-Oh Park, S. Ou, C. Park, 2013, Modern Pathology.

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

C. Paweletz, M. Kris, P. Jänne, 2014, The Lancet. Oncology.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

J. Shih, L. Sequist, S. Ou, 2012, The Lancet. Oncology.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

J. Fernandez-Banet, A. Pavlícek, J. Christensen, 2019, Cancer discovery.

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Patrick Schöffski, Keith Steele, J. Nemunaitis, 2015 .

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.

S. Ou, Wei Li, Shuanying Yang, 2021, Clinical lung cancer.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2012, The Lancet. Oncology.

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

Vamsidhar Velcheti, Philip J. Stephens, Vincent A. Miller, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

S. C. Wang, A. Iafrate, A. Shaw, 2019 .

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

R. Govindan, J. Ahn, S. Ou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.

S. Digumarthy, A. Shaw, B. Yeap, 2018 .

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

H. Wakelee, L. Sequist, S. Ou, 2014 .

The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.

A. Shaw, S. Ou, J. Gainor, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Xiaohong Yan, P. Jänne, A. Tolcher, 2021 .

BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.

S. Ganesan, M. Rosenzweig, S. Ou, 2018, JCO precision oncology.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

P. Stephens, S. Ou, V. Miller, 2017, Lung cancer.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

S. Ou, V. Miller, Siraj M. Ali, 2017, Lung cancer.

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

P. Stephens, S. Ou, V. Miller, 2017, Clinical lung cancer.

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.

S. Ou, Siraj M. Ali, N. Agarwal, 2016, Lung cancer.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

P. Stephens, M. Erlander, S. Ou, 2016, Cancer discovery.

Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer

P. Stephens, S. Ou, V. Miller, 2016 .

Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation

S. Ou, R. Doebele, A. Dimou, 2019, JCO precision oncology.

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

A. Shaw, S. Ou, T. Mok, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

P. Stephens, S. Ou, V. Miller, 2017, Lung cancer.

Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?

S. Ou, 2014, Postgraduate Medical Journal.

Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?

S. Ou, 2013, Journal of Clinical Pathology.

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

A. Drilon, S. Ou, D. Camidge, 2022, Cancer discovery.

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

M. Lawrence, S. Digumarthy, A. Drilon, 2021, Clinical Cancer Research.

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

S. Ou, Siraj M. Ali, A. Schrock, 2018, Lung Cancer.

Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.

S. Ou, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.

S. Ou, K. Shirai, 2016, Advances in experimental medicine and biology.

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

S. Ou, Michele C. Azada, Stephanie Y Lu, 2015, Lung cancer.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

P. Jänne, S. Ou, Gregory Riely, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

S. Ou, S. Ou, J. Kim, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Medicine in Practice The EGFR T 790 M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2012 .

Title : The EGFR T 790 M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2011 .

Predictive Biomarkers and Personalized Medicine ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1 , 683 Patients with Non – Small Cell Lung Cancer

M. Ladanyi, A. Iafrate, M. Mino‐Kenudson, 2013 .

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

A. Iafrate, A. Shaw, S. Ou, 2010 .

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

Jeffrey W. Clark, A. Drilon, R. Heist, 2019, Nature Medicine.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Jeffrey W. Clark, A. Drilon, P. Jänne, 2019, Lung cancer.

Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer.

S. Ou, B. Halmos, A. Muzikansky, 2006, Clinical lung cancer.

ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.

Edward S. Kim, S. Ou, M. Ahn, 2021, Future oncology.

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC

A. Shaw, B. Yeap, S. Ou, 2020, JTO clinical and research reports.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

D. Jäger, P. Ascierto, J. Nemunaitis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2019, European journal of cancer.

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomize

S. Ou, H. Saka, M. Ando, 2015, The oncologist.

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

S. Digumarthy, A. Drilon, M. Arcila, 2021, JTO clinical and research reports.

Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2012 .

Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers

M. Kris, P. Jänne, S. Ou, 2012 .

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

I. Wistuba, F. Hirsch, S. Ou, 2015, The oncologist.

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

A. Mansfield, S. Ou, R. Salgia, 2022, Journal of Clinical Oncology.

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Jeffrey W. Clark, S. Ou, S. Ou, 2018 .

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

P. Jänne, J. Riess, S. Ou, 2020 .

NTRK fusion positive colorectal cancer as a unique subset of CRC with high tumor mutation burden and microsatellite instability.

S. Ou, Hui Wang, Xue Wu, 2021 .

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

A. Drilon, A. Graber, A. Shaw, 2019, Clinical Research (Excluding Clinical Trials).

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, L. Sequist, S. Ou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

S. Ou, V. Zhu, 2020, JTO clinical and research reports.

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy.

S. Ou, T. Mok, M. Loh, 2012, Future oncology.

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

S. Ou, S. Klempner, C. Duma, 2015, Lung cancer.

Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

P. Jänne, S. Ou, Keunchil Park, 2016 .

1OComprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types

S. Ikeda, S. Ganesan, S. Ou, 2017 .

Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC

S. Digumarthy, A. Shaw, B. Yeap, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials

D. Tenen, S. Ou, T. Mok, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

S. Ou, Adam S. Barnett, P. Rosenberg, 2017, Cardio-Oncology.

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)

S. Ou, K. Wilner, Yiyun Tang, 2016, Cancer medicine.

Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

A. Shaw, S. Ou, T. Mok, 2019, Annals of Oncology.

LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2022, Annals of Oncology.

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).

A. Drilon, S. Ou, A. Shaw, 2019, Journal of Clinical Oncology.

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

S. C. Wang, Jeffrey W. Clark, A. Shaw, 2016 .

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

H. Wakelee, L. Sequist, S. Ou, 2016 .

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

S. Ou, Siraj M. Ali, A. Schrock, 2019, Lung Cancer.

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

S. Ou, R. Soo, M. Nagasaka, 2020, Translational lung cancer research.

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

A. Shaw, S. Ou, Gregory Riely, 2019, The Lancet. Oncology.

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

P. Stephens, S. Ou, V. Miller, 2016, The oncologist.

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.

S. Ou, Jeeyun Lee, 2013, Discovery medicine.

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.

S. Ou, Jeeyun Lee, Jeeyun Lee, 2013, Discovery medicine.

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature

S. Ou, H. Tukachinsky, Shannon S Zhang, 2022, JTO clinical and research reports.

METex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?

S. Ou, V. Zhu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.

S. Ou, D. Kelly, S. Klempner, 2016, Lung cancer.

OA 12.08 Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification

S. Ou, V. Miller, Siraj M. Ali, 2017 .

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of Clinical Oncology.

MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

S. Ou, V. Miller, Siraj M. Ali, 2017 .

OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

S. C. Wang, A. Drilon, R. Heist, 2018, Journal of Thoracic Oncology.

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

J. Nieva, S. Ou, P. Bunn, 2013, Cancer.

And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.

S. Ou, S. Lau, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)

James X. Sun, P. Stephens, S. Ou, 2017 .

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.

OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer

A. Shaw, S. Ou, E. Felip, 2017 .

Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?

S. Ou, S. Lau, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

From preclinical efficacy to 2022 updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.

S. Ou, M. Nagasaka, Alexandria T M Lee, 2023, Critical reviews in oncology/hematology.

Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.

A. Shaw, S. Ou, E. Felip, 2017 .

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

P. Jänne, A. Shaw, S. Ou, 2020, JTO clinical and research reports.

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.

A. Shaw, S. Ou, T. Mok, 2020 .

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Riess, S. Ou, J. Bendell, 2020, European Journal of Cancer.

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

P. Jänne, S. Ou, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).

V. Wang, S. Ganesan, S. Ou, 2017 .

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors

S. Ou, M. Brose, V. Subbiah, 2018, Clinical Trials.

NTRK1-3 genomic fusions in non-small cell lung cancer (NSCLC) determined by comprehensive genomic profiling

E. Sokol, S. Ou, G. Frampton, 2019, Annals of Oncology.

Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?

Edward S. Kim, S. Ou, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study

S. Ou, T. Mok, S. Peters, 2017 .

SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).

S. Ou, A. Wozniak, D. Gandara, 2012 .

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

S. Ou, A. Joe, H. Prenen, 2022, European Journal of Cancer.

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

S. Ou, M. Nagasaka, D. Brazel, 2023, Lung Cancer.

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.

S. Ou, Jianchang Lin, Pingkuan Zhang, 2023, Lung cancer.

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

S. Ou, V. Miller, Siraj M. Ali, 2018, Lung cancer.

First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers

M. Kris, P. Jänne, S. Ou, 2012 .

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

S. Ou, A. Joe, A. Schram, 2021, Journal of Clinical Oncology.

1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2017 .

Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.

A. Shaw, S. Ou, R. Salgia, 2012 .

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

A. Dingemans, S. Ou, F. Barlesi, 2016 .

MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

M. Socinski, A. Shaw, S. Ou, 2017 .

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

A. Drilon, S. Ou, M. Ahn, 2020 .

MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)

M. Rosenzweig, S. Ou, V. Miller, 2018, Journal of Thoracic Oncology.

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

S. Ou, K. Steele, M. Rebelatto, 2016 .

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017 .

1001P Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US

S. Ou, Y. Wu, Z. Piotrowska, 2022, Annals of Oncology.

Chemotherapy is beneficial for elderly patients with advanced non-small-cell lung cancer: analysis of patients aged 70-74, 75-79, and 80 or older in Japan.

S. Ou, R. Saito, M. Arao, 2012, Clinical lung cancer.

MA07.09 BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study

S. Ou, D-W. Kim, T.M. Kim, 2022, Journal of Thoracic Oncology.

14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)

S. Ou, P. Janne, K. Li, 2023, Journal of Thoracic Oncology.

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.

S. Ou, Y. Ohe, E. Felip, 2023, Future oncology.

A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).

G. Scagliotti, A. Shaw, S. Gettinger, 2012 .

Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity

J. Zell, A. Ziogas, S. Ou, 2008 .

Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.

J. Neal, S. Ou, Jianchang Lin, 2023, Lung cancer.

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

A. Dingemans, A. Shaw, S. Ou, 2017, British Journal of Cancer.

Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK‐Positive Non–Small‐Cell Lung Cancer: Histologic Analysis

S. Ou, V. Zhu, Yuxin Lu, 2019, Clinical lung cancer.

Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).

Aaron M. Newman, A. Shaw, S. Ou, 2016 .

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.

S. Gettinger, S. Ou, M. Ahn, 2017 .

OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6

A. Shaw, S. Ou, Gregory Riely, 2018, Journal of Thoracic Oncology.

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

C. Paweletz, M. Kris, P. Jänne, 2014, The Lancet. Oncology.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Manish B. Patel, A. Iafrate, A. Drilon, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

Reply to "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023;18(2):158-168".

S. Ou, N. Triphuridet, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.